Statement: the primary trial records a significant amount of heart-related adverse events and the secondary one records various infection related issues, but they both show no records of epilepsy
Primary_evidence: Adverse Events 1:   Total: 0/655 (0.00%) Adverse Events 2:   Total: 0/580 (0.00%)
Secondary_evidence: Adverse Events 1:   Total: 0/15 (0.00%) Adverse Events 2:   Total: 0/16 (0.00%)